SUNRISE, Fla., Nov. 14, 2011 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT) today released a short clip from the American Investor Documentary. William P. Murphy Jr., MD talks about the unrealized opportunities with the Bioheart technology and the strong management team leading the efforts.
Dr. Murphy has served as a member of Bioheart's Board of Directors since June 2003 and is currently serving as the Chairman of the Board. Murphy, son of a Nobel Prize winner in medicine, is a pioneer in applying engineering to medicine. His many successful medical devices include disposable medical procedure trays, blood bags, physiologic cardiac pacemakers, angiographic injectors, and hollow fiber artificial kidneys. In 1957, he founded Medical Development Corporation in his garage. Soon after, it became Cordis Corporation, which today, as a subsidiary of Johnson & Johnson, focuses on developing medical instrumentation. Murphy also founded Small Parts, Inc., acquired by Amazon.com, which provides small and large quantities of specialized materials and tools to engineers. He is the recipient of a number of honors, including the prestigious induction into the National Inventors Hall of Fame.
Bioheart's president and CEO, Mike Tomas said, "Having the endorsement and continued support from a visionary in the field like Dr. Murphy is truly an honor. Bioheart's stem cell technology could revolutionize the field of medicine for cardiac patients."
Click here to view Dr. Murphy on The American Investor
http://www.youtube.com/watch?v=zSwRyMNl5Ps
About The American Investor
The American Investor produces the national and international award winning program ABC's "Money Talks", ABC's "MoneyScope" and The American & Smart Consumer on PBS.
About Bioheart, Inc
Bioheart is focused on completing the Phase II/III MARVEL study for chronic heart failure using MyoCell. The product candidate has been in clinical trials since May of 2001 with the goal of commercial approval with the current clinical program. There are approximately 130 more patients needed to complete the randomized, double blinded, placebo controlled MARVEL trial. In part one of the MARVEL trial, the performance of MyoCell was nearly 500% above its primary end point goal of 16 meters improvement in exercise capacity testing. MyoCell treated patients improved 91.7 meters while placebo patients declined 4 meters.
MyoCell is a muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the intended purpose of improving cardiac function and quality of life in chronic heart failure patients.
For more information on Bioheart, visit www.globenewswire.com/newsroom/ctr%3Fd=227994%26l=7%26a=http%253A%252F%252Fwww.bioheartinc.com%26u=http%253A%252F%252Fus.lrd.yahoo.com%252F_ylt%253DAlOSZ9CEXfT3uibZcyJcgLWxcq9_%253B_ylu%253DX3oDMTE2cnJmdW9hBHBvcwMxBHNlYwNuZXdzYXJ0Ym9keQRzbGsDaHR0cHd3d2Jpb2hl%252FSIG%253D11fguppga%252FEXP%253D1312565712%252F%252A%252Ahttp%25253A%252Fwww.bioheartinc.com%252F">http://www.bioheartinc.com.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2011.